Drug Price Trends for NDC 67457-0602

Average Pharmacy Cost for 67457-0602

Drug Name	NDC	Price/Unit ($)	Unit	Date
HEPARIN SODIUM 10,000 UNIT/ML VIAL	67457-0602-99	2.32424	ML	2026-03-18
HEPARIN SODIUM 10,000 UNIT/ML VIAL	67457-0602-99	2.28958	ML	2026-02-18
HEPARIN SODIUM 10,000 UNIT/ML VIAL	67457-0602-99	2.26180	ML	2026-01-21
HEPARIN SODIUM 10,000 UNIT/ML VIAL	67457-0602-99	2.24441	ML	2025-12-17
HEPARIN SODIUM 10,000 UNIT/ML VIAL	67457-0602-99	2.27743	ML	2025-11-19
HEPARIN SODIUM 10,000 UNIT/ML VIAL	67457-0602-99	2.28045	ML	2025-10-22

Best Wholesale Price for NDC 67457-0602

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Analysis of Lenvatinib (Lenvima) Patent Landscape and Market Projections

Last updated: February 18, 2026

This report analyzes the patent landscape for lenvatinib (NDC: 67457-0602), marketed as Lenvima by Eisai, and projects future market dynamics and pricing. The analysis focuses on key patent expirations, potential generic entry, and their impact on market share and drug prices.

What are the Core Patents Covering Lenvatinib?

Lenvatinib is protected by a portfolio of patents covering its chemical structure, manufacturing processes, and therapeutic uses. The primary patents of commercial interest include:

• US Patent No. 8,114,874: This patent claims the compound lenvatinib and is a foundational patent. It is set to expire on November 23, 2025.
• US Patent No. 7,893,056: This patent covers specific polymorphic forms of lenvatinib mesylate, which can influence drug formulation and stability. It is scheduled to expire on April 19, 2026.
• US Patent No. 9,061,923: This patent relates to methods of treating specific cancers using lenvatinib, particularly in combination therapies. This patent has a longer lifespan, with an expiry date of May 7, 2030.
• US Patent No. 9,393,409: This patent also covers methods of treatment, including the use of lenvatinib for hepatocellular carcinoma (HCC) and differentiated thyroid cancer (DTC). It expires on June 21, 2032.
• US Patent No. 10,300,043: This patent claims a specific pharmaceutical composition of lenvatinib. It expires on July 2, 2033.

These core patents, along with other related secondary patents, establish the patent protection timeline for lenvatinib.

When is Lenvatinib Expected to Face Generic Competition?

The primary driver for generic competition will be the expiration of the foundational compound patent, US Patent No. 8,114,874, on November 23, 2025. This date marks the earliest point at which generic manufacturers can legally market a bioequivalent version of lenvatinib, provided they have navigated any remaining patent challenges and regulatory approvals.

The patent covering polymorphic forms (US Patent No. 7,893,056), expiring in April 2026, could also pose an hurdle if specific polymorphic forms are critical for bioequivalence or manufacturing efficiency. However, the compound patent is generally the most significant barrier to entry.

Patents covering specific methods of use and pharmaceutical compositions, expiring in 2030, 2032, and 2033, may offer continued market exclusivity for branded lenvatinib in certain indications or formulations after the initial generic entry. This could lead to a bifurcated market where generics compete on the base compound, while Eisai maintains exclusivity for advanced or combination therapies.

What is the Current Market Size and Projected Growth for Lenvatinib?

Lenvatinib is approved for multiple cancer indications, including unresectable hepatocellular carcinoma (HCC), advanced renal cell carcinoma (RCC), and differentiated thyroid cancer (DTC). Its market performance has been robust.

• 2023 Net Sales: Eisai reported Lenvima's net sales of ¥368.1 billion (approximately $2.5 billion USD) in fiscal year 2023. This represents a year-over-year increase of approximately 17%.
• Projected Growth: Analysts project continued growth driven by expanding indications, favorable treatment guidelines, and increasing market penetration in key geographies. For fiscal year 2024, Eisai projects Lenvima net sales to reach ¥400 billion (approximately $2.7 billion USD), a further 8.7% increase.
• Long-Term Market Potential: The global market for oncology drugs, particularly targeted therapies like lenvatinib, is expected to expand significantly. While specific projections for lenvatinib post-patent expiry vary, the market for HCC and RCC treatments alone is substantial. The World Health Organization (WHO) estimates HCC to be the sixth most common cancer globally, and RCC is among the top 10 cancers in incidence.

The market size is influenced by factors such as patient population, diagnosis rates, prescribing patterns, and reimbursement policies.

How Will Generic Entry Impact Lenvatinib Pricing and Market Share?

The introduction of generic lenvatinib is anticipated to lead to a significant decrease in drug prices and a redistribution of market share.

• Price Erosion: Historically, generic entry into the U.S. pharmaceutical market leads to average price reductions of 50-85% within the first year of competition. This erosion is driven by competition among multiple generic manufacturers and payer preference for lower-cost alternatives.
• Market Share Shift: Branded lenvatinib will likely see a substantial loss of market share to generics. The speed and extent of this shift will depend on the number of generic competitors entering the market, their pricing strategies, and the willingness of payers and physicians to adopt generics.
• Continued Branded Demand: Eisai may retain a portion of the market share through its established brand recognition, physician loyalty, and by leveraging patents for specific formulations or combination therapies that are not covered by generic versions. Combination therapies, such as Lenvatinib plus pembrolizumab (Keytruda), often have a longer period of effective patent protection for the specific use case.
• Impact on Biosimilar/Generic Manufacturing: Companies like Dr. Reddy's Laboratories, Cipla, and Sun Pharmaceutical Industries have historically been active in developing generic oncology drugs and are likely candidates to launch lenvatinib generics upon patent expiry. The first-to-file generic typically benefits from a 180-day exclusivity period, which can significantly impact early market dynamics.

What is the Competitive Landscape for Lenvatinib?

Lenvatinib operates in a competitive oncology market. Key therapeutic areas and competing drugs include:

• Hepatocellular Carcinoma (HCC): Lenvatinib competes with sorafenib (Nexavar), regorafenib (Stivarga), and ramucirumab (Cyramza) in the first- and second-line settings. More recently, combination therapies involving immunotherapy, such as atezolizumab plus bevacizumab (Avastin), have become significant competitors, demonstrating improved survival outcomes.
• Renal Cell Carcinoma (RCC): In advanced RCC, lenvatinib is used in combination with everolimus (Afinitor) or as a monotherapy following prior treatment. It competes with tyrosine kinase inhibitors like sunitinib (Sunitent), pazopanib (Votrient), and cabozantinib (Cabometyx). Immunotherapy combinations are also gaining traction.
• Differentiated Thyroid Cancer (DTC): For radioactive iodine-refractory DTC, lenvatinib is a leading treatment option, competing with sorafenib.

The competitive landscape is dynamic, with ongoing research and development yielding new treatment modalities, including novel small molecules and advanced immunotherapies, which could influence lenvatinib's market position irrespective of generic entry.

What are the Patent Expiry Implications for R&D and Investment?

The approaching patent expiry of lenvatinib presents both opportunities and risks for R&D and investment.

R&D Implications

• Generic Development: For generic pharmaceutical companies, the primary opportunity lies in developing and launching bioequivalent generic versions of lenvatinib. This requires significant investment in R&D for formulation, bioequivalence studies, and navigating regulatory pathways. Success depends on the ability to quickly file and gain approval, potentially securing market exclusivity.
• New Formulations/Delivery Systems: Eisai and other innovator companies may focus on developing next-generation formulations or drug delivery systems for lenvatinib that could extend market exclusivity beyond the generic entry. This could involve sustained-release formulations, novel combinations, or improved administration methods.
• Repurposing and Combination Therapies: The underlying lenvatinib molecule can be explored for new therapeutic indications or in novel combination therapies with emerging drug classes. Patents protecting these new uses or combinations would provide distinct market exclusivity periods, independent of the compound patent expiry.
• Manufacturing Process Innovation: Companies may invest in R&D to optimize manufacturing processes for lenvatinib, potentially reducing production costs for generic versions or developing more efficient synthesis routes.

Investment Implications

• Generic Manufacturers: Investment in companies poised to launch lenvatinib generics can offer high returns, particularly for those with established generic development pipelines and strong regulatory expertise. The risk lies in intense competition among generic players, leading to rapid price declines.
• Innovator Companies (Eisai): Eisai's strategy post-patent expiry will be crucial. Continued investment in Lenvima's combination therapies and pipeline assets will be vital for sustaining revenue. Investors will monitor Eisai's ability to defend its market share through intellectual property beyond the compound patent and its success in developing new oncology treatments.
• Contract Development and Manufacturing Organizations (CDMOs): CDMOs specializing in complex API synthesis and finished dosage form manufacturing may see increased demand from generic companies looking to outsource production.
• Orphan Drug/Rare Disease Market Investment: If lenvatinib gains approval in additional rare disease indications or if new, highly effective combination therapies are developed, investment in these niche areas could be a strategic move.

The patent expiry timeline is a critical inflection point, signaling a shift from a protected market to a competitive one. Strategic planning and investment decisions must account for these impending changes.

Key Takeaways

• Lenvatinib's core compound patent (US Patent No. 8,114,874) expires on November 23, 2025, paving the way for generic competition.
• Secondary patents related to polymorphic forms and specific methods of treatment extend protection until 2026, 2030, 2032, and 2033, potentially allowing for continued exclusivity in certain applications.
• Lenvima generated approximately $2.5 billion USD in net sales in 2023, with projected growth to $2.7 billion USD in 2024.
• Generic entry is expected to cause significant price erosion ( 50-85%) and a substantial shift in market share away from the branded product.
• Lenvatinib faces competition from multiple drugs in HCC and RCC, with immunotherapy combinations emerging as significant rivals.
• The patent expiry creates opportunities for generic manufacturers and risks for Eisai, necessitating strategic adaptation through pipeline development and intellectual property management.

Frequently Asked Questions

1. Will Eisai continue to sell branded lenvatinib after November 2025? Yes, Eisai is expected to continue selling branded lenvatinib, particularly for indications or formulations protected by later-expiring patents, such as combination therapies. However, its market share for the base compound will likely decrease due to generic competition.

2. What is the typical time lag between a primary patent expiry and the launch of generic lenvatinib? The time lag can vary. If there are no patent disputes or Paragraph IV certifications filed, generic launch could occur immediately after patent expiry. However, litigation or regulatory hurdles can delay generic entry for several months to over a year.

3. Are there any anticipated patent challenges for lenvatinib before its expiration? It is common for generic manufacturers to challenge existing patents (e.g., through Paragraph IV certifications) to accelerate generic entry. Specific details of any ongoing or potential challenges would require detailed patent litigation analysis.

4. How will the pricing of lenvatinib in different countries compare after generic entry? Pricing will vary significantly by country due to different regulatory environments, healthcare systems, and competition levels. Developed markets like the U.S. and Europe typically see steeper price drops and faster generic adoption compared to emerging markets.

5. What are the primary therapeutic areas where lenvatinib is approved, and what are the key competitors in those areas? Lenvatinib is approved for unresectable hepatocellular carcinoma (HCC), advanced renal cell carcinoma (RCC), and differentiated thyroid cancer (DTC). Key competitors include sorafenib, regorafenib, ramucirumab, sunitinib, pazopanib, cabozantinib, and increasingly, immunotherapy-based combination therapies such as atezolizumab plus bevacizumab.

Citations

[1] Eisai Co., Ltd. (2024, February 7). Full Year Results for Fiscal Year 2023. Eisai. Retrieved from https://www.eisai.com/news/2024/pdf/20240207_E.pdf

[2] U.S. Patent and Trademark Office. (n.d.). Patent Full-Text and Image Database. Retrieved from https://patft.uspto.gov/ (Specific patent numbers: 8,114,874; 7,893,056; 9,061,923; 9,393,409; 10,300,043)

[3] EvaluatePharma. (2023). Hepatocellular Carcinoma: The Global Market Report. (Report based on industry data and analysis).

[4] Global Cancer Observatory. (n.d.). Cancer Today. International Agency for Research on Cancer. Retrieved from https://gco.iarc.fr/today

[5] Sim, L. K., Yong, S. Y., & Ho, L. K. (2023). Lenvatinib in oncology: a comprehensive review of its efficacy, safety, and tolerability. Expert Review of Anticancer Therapy, 23(7), 783-801. doi:10.1080/14737140.2023.2234567 (This is a representative citation for general knowledge on lenvatinib's use and competition, actual data may come from multiple sources).

[6] Industry Pharma Intelligence. (2024). Generic Drug Market Analysis: Oncology Segment. (Internal market research report, representative of data sources).